Vapotherm Inc VAPO
We take great care to ensure that the data presented and summarized in this overview for VAPOTHERM INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VAPO
View all-
Parian Global Management LP Pound Ridge, NY1.18MShares$2.55 Million6.0% of portfolio
-
Prescott Investors Profit Sharing Trust Boca Raton, FL86.4KShares$187,5890.29% of portfolio
-
Smith Thomas W Boca Raton, FL17.1KShares$37,1610.05% of portfolio
-
Brinker Capital Investments, LLC15.9KShares$34,4790.0% of portfolio
Latest Institutional Activity in VAPO
Top Purchases
Top Sells
About VAPO
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.
Insider Transactions at VAPO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 20
2024
|
Anthony L. Arnerich Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
221,189
-100.0%
|
$442,378
$2.18 P/Share
|
Sep 20
2024
|
Anthony L. Arnerich Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,804
-100.0%
|
$23,608
$2.18 P/Share
|
Sep 20
2024
|
Joseph Army President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
40,687
-100.0%
|
-
|
Sep 20
2024
|
Joseph Army President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
412,011
-100.0%
|
$824,022
$2.18 P/Share
|
Sep 20
2024
|
John Landry SVP & Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,305
-100.0%
|
-
|
Sep 20
2024
|
John Landry SVP & Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
69,356
-100.0%
|
$138,712
$2.18 P/Share
|
Sep 20
2024
|
Brian Lawrence SVP & Chief Technology Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
60,188
-100.0%
|
$120,376
$2.18 P/Share
|
Sep 20
2024
|
Dorota Mc Kay VP, Controller and CAO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,371
-100.0%
|
$42,742
$2.18 P/Share
|
Sep 20
2024
|
James W Liken Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
54,808
-100.0%
|
$109,616
$2.18 P/Share
|
Sep 20
2024
|
Elizabeth H Weatherman Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
81,546
-100.0%
|
$163,092
$2.18 P/Share
|
Sep 20
2024
|
Elizabeth H Weatherman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,555
-100.0%
|
$35,110
$2.18 P/Share
|
Sep 20
2024
|
Lori Lynn Knowles Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,237
-100.0%
|
$20,474
$2.18 P/Share
|
Sep 20
2024
|
Mary Beth Moynihan Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,852
-100.0%
|
$21,704
$2.18 P/Share
|
Sep 20
2024
|
Lance A Berry Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
25,485
-100.0%
|
$50,970
$2.18 P/Share
|
Sep 20
2024
|
Donald J Spence Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,696
-100.0%
|
$25,392
$2.18 P/Share
|
Jan 22
2024
|
James W Liken Director |
SELL
Open market or private sale
|
Direct |
17,500
-25.81%
|
$0
$0.91 P/Share
|
Jan 01
2024
|
Elizabeth H Weatherman Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+25.47%
|
$60,000
$10.0 P/Share
|
Jan 01
2024
|
Donald J Spence Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+32.09%
|
$60,000
$10.0 P/Share
|
Jan 01
2024
|
Mary Beth Moynihan Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+31.54%
|
$50,000
$10.0 P/Share
|
Jan 01
2024
|
James W Liken Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+11.07%
|
$90,000
$10.0 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 42K shares |
---|
Sale (or disposition) back to the issuer | 1.05M shares |
---|---|
Open market or private sale | 17.5K shares |